ItalyResearchers have identified dendritic cells, a type of white blood cell, as the key immune cells responsible for building 'anti-cancer outposts' within tumors. These structures, known as tertiary lymphoid structures (TLS), act as local command centers to coordinate immune attacks directly inside the tumor. The study, published in the journal Science by researchers at the Icahn School of Medicine at Mount Sinai in New York, suggests that targeting these dendritic cells could improve cancer immunotherapy. Current immunotherapies primarily focus on activating T-cells, but this research highlights the potential of therapies that either activate existing dendritic cells in the tumor tissue or recruit more of them. Such treatments could be particularly beneficial for patients who do not respond well to traditional immunotherapy.
Bias read (Center): The article discusses scientific research related to cancer immunology and does not take a stance on any political issue. It presents findings from academic research and quotes scientists without apparent ideological framing.
